N-甲基-1-苯基-2-(吡咯烷基-1-基)乙-1-胺 | 130110-09-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基-1-苯基-2-(吡咯烷基-1-基)乙-1-胺
• 英文名称: N-methyl-1-phenyl-2-(pyrrolidin-1-yl)ethan-1-amine
• 英文别名: methyl-[1-(S)-phenyl-2-pyrrolidin-1-yl-ethyl]-amine；(1-Phenyl-2-pyrrolidinylethyl)methylamine；N-methyl-1-phenyl-2-pyrrolidin-1-ylethanamine
• CAS: 130110-09-7
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: ZINZYRWMDNKTBY-UHFFFAOYSA-N

物化性质

• 沸点：
  296.1±20.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-甲基-1-苯基-2-(吡咯烷基-1-基)乙-1-胺 在 硫酸 、 N,N'-羰基二咪唑 作用下， 反应 28.5h， 生成 trans-1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-<(3,4-dichloro)phenyl>-1,2,3,4-tetrahydroisoquinolin-3-(2H)-one
  参考文献：
  名称：

  Synthesis and κ binding affinity of 1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-[(3,4-dichloro)phenyl]-1,2,3,4 tetrahydroisoquinolin-3(2H)-ones

  摘要：

  Diastereomeric forms of 1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-[(3,4-dichloro)phenyl]-1,2,3,4-tetrahydroisoquinoline-3(2h)-ones 3a and its chloro analog 3c were synthesized. Compounds 3a,c are related to the kappa-selective opiate ICI 199441 1 by linking the benzylic CH2 to the ortho position of the phenyl in 1. Compared with morphine, these compounds had lost in kappa and mu affinities; only cis-3a showed a modest kappa affinity. 1-Pyrrolidin-1-ylmethyl-N-[2-(3,4-dichlorphenyl)acetyl]-1,2,3,4-tetrahydroisoquinoline 2, which is also a cyclic congener of 1, was reported to display high kappa and mu affinity, and so a conformational study was undertaken on 1, 2 and 3a. This showed that, while active 2 extensively superposed on 1, 3a assumes another geometry which does not allow a fit with the pharmacophoric moieties of 1 and 2.

  DOI：

  10.1016/0223-5234(96)88263-8
• 作为产物：
  描述：

  2-氨基-2-苯基乙酸 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 N,N'-羰基二咪唑 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 N-甲基-1-苯基-2-(吡咯烷基-1-基)乙-1-胺
  参考文献：
  名称：

  Synthesis and κ binding affinity of 1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-[(3,4-dichloro)phenyl]-1,2,3,4 tetrahydroisoquinolin-3(2H)-ones

  摘要：

  Diastereomeric forms of 1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-[(3,4-dichloro)phenyl]-1,2,3,4-tetrahydroisoquinoline-3(2h)-ones 3a and its chloro analog 3c were synthesized. Compounds 3a,c are related to the kappa-selective opiate ICI 199441 1 by linking the benzylic CH2 to the ortho position of the phenyl in 1. Compared with morphine, these compounds had lost in kappa and mu affinities; only cis-3a showed a modest kappa affinity. 1-Pyrrolidin-1-ylmethyl-N-[2-(3,4-dichlorphenyl)acetyl]-1,2,3,4-tetrahydroisoquinoline 2, which is also a cyclic congener of 1, was reported to display high kappa and mu affinity, and so a conformational study was undertaken on 1, 2 and 3a. This showed that, while active 2 extensively superposed on 1, 3a assumes another geometry which does not allow a fit with the pharmacophoric moieties of 1 and 2.

  DOI：

  10.1016/0223-5234(96)88263-8
• 作为试剂：
  描述：

  1,4-环己二烯 在 咪唑 、 甲醇 、 potassium iodate 、 重铬酸吡啶 、 正丁基锂 、 Amberlite IRA(OH) 、 碘 、 potassium acetate 、 N-甲基-1-苯基-2-(吡咯烷基-1-基)乙-1-胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 58.5h， 生成 (4S,5R)-4,5-bis(tert-butyldimethylsilyloxy)cyclohex-2-enone
  参考文献：
  名称：

  O'Brien, Peter; Poumellec, Pierre, Journal of the Chemical Society. Perkin transactions I, 1998, # 15, p. 2435 - 2441

  摘要：

  DOI：

文献信息

• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005095343A1

  公开（公告）日：2005-10-13

  The invention relates to compounds of formula (I), Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>), wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。
• Sulfonylamino phenylacetamide derivatives and methods of their use
  申请人：——

  公开号：US20040254156A1

  公开（公告）日：2004-12-16

  Sulfonylamino phenylacetamide derivatives of the general formula 1 are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to &kgr; opioid receptors; (2) display good opioid receptor selectivity of &kgr; versus &mgr; and &kgr; versus &dgr;; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

  揭示了通式1的磺酰氨基苯乙酰胺衍生物。还公开了含有这些化合物的药物组合物和它们的使用方法。在某些实施例中，本发明的化合物最好具有以下特征：(1) 与κ阿片受体结合的亲和力高；(2) 在κ与μ受体以及κ与δ受体之间显示良好的阿片受体选择性；以及(3) 不显著抑制细胞色素P450酶的活性，特别是CYP2D6、CYP2C9和CYP3A4。
• PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140243338A1

  公开（公告）日：2014-08-28

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Structure activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective .kappa.-opioid agonists
  作者：Jeffrey J. Barlow、Thomas P. Blackburn、Gerard F. Costello、Roger James、David J. Le Count、Brian G. Main、Robert J. Pearce、Keith Russell、John S. Shaw

  DOI：10.1021/jm00115a001

  日期：1991.11

  optimum was found to be exemplified by 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(1-methylethyl)-2- (1-pyrrolidinyl)ethyl]acetamide (13). Subsequently, racemic or chiral amino acids were used to introduce other alkyl and aryl substituents at C1 of the ethyl linking moiety. A series of potent compounds, bearing substituted-aryl groups at C1, were discovered, typified by 2-(3,4-dichloro-phenyl)-N-methyl-N-[(1R

  本文描述了一系列N- [2-（1-吡咯烷基）乙基]乙酰胺及其相关类似物的合成，以及它们作为阿片样物质的生物学评价，这些酰胺在邻近酰胺氮（C1）的碳上被取代。激动剂。在研究的第一部分中，研究了当C1处的取代基为1-甲基乙基时，N-酰基，N-烷基和氨基官能团的变异体，并以2-（3,4-二氯苯基）为例进行了研究。 ）-N-甲基-N-[（1S）-1-（1-甲基乙基）-2-（1-吡咯烷基）乙基]乙酰胺（13）。随后，使用外消旋或手性氨基酸在乙基连接部分的C1处引入其他烷基和芳基取代基。发现了一系列在C1上带有取代芳基的有效化合物，其典型值为2-（3,4-二氯-苯基）-N-甲基-N-[（1R，